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The purpose of this study was to project mortality rates in the United Kingdom for the period 2006–2025 for 21 major cancers on
the basis of the observed trends in mortality rates during 1971–2005, and to estimate the implication in terms of expected deaths.
Age-period-cohort models were applied to official statistics. The projected decrease in age-standardised mortality rates for all
cancers from 2003 to 2023 was 17% in men and 16% in women. Future mortality rates were projected to decline for most cancer
sites. In men, there were small projected increases in mortality rates from cancers of the oral cavity, oesophagus and melanoma, with
a larger projected increase (14% over 20 years) in mortality of liver cancer. In women, the only projected increase (18%) was for
corpus uteri. The numbers of deaths will increase for most cancers, with a 30% increase in all cancers projected for men and a 12%
increase projected for women. Mortality rates from cancer as a whole have been falling in the United Kingdom since 1990, and this
decline was projected to continue into the future as well as the declining rates in both sexes for most cancers. Actual numbers of
deaths will increase for most cancers.
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Projections of cancer incidence and mortality provide an estimate
of the future burden of cancer and are fundamental to the process
of planning for programmes of cancer control as well as for setting
priorities for future research. In addition, by providing a bench-
mark of the expected rates of disease given current exposure to
aetiological factors and healthcare interventions, projections
become a valuable tool in evaluating the effectiveness of new
programmes that aim to reduce incidence, mortality or both (Bray
and Møller, 2006).
When predicting future incidence and mortality rates, it is
necessary to be aware of the underlying assumptions and
limitations. A distinction is sometimes made between projections
and forecasts (Bashir and Este `ve, 2001). Projections derive from an
extension into the future of past trends in rates of disease. By
contrast, forecasts represent estimation of future rates taking into
account expected changes in the factors determining the risk, or
outcome, of the disease concerned.
In this report, we present projections of mortality rates of cancer
in the United Kingdom to the period 2006–2025 for 21 major
cancers on the basis of the observed trends in mortality rates
during 1971–2005, and estimate the implication in terms of
expected deaths, using government population projections.
MATERIALS AND METHODS
The number of cancer deaths in the United Kingdom by cancer
site, sex, 5-year age group and year for the 35-year period from
1971 to 2005, and population numbers for the same years and age–
sex groups were provided by Cancer Research UK on the basis
of separate national data from England, Scotland, Wales and
Northern Ireland.
Population projections (2006 based) for the United Kingdom by
sex, 5-year age group and year from 2006 to 2025 were downloaded
from the Government Actuary’s Department (2007).
The R-based software, ‘Nordpred’, developed at the Norwegian
Cancer Registry for projections of nordic incidence and mortality
rates (Møller et al, 2002), was used to project mortality rates in
2006–2025. The calculations are on the basis of the mortality
rates from 1971 to 2005, aggregated into 5-year time periods from
1971–1975 to 2001–2005.
Future numbers of deaths were projected by multiplying the
projected age-specific rates by the population projections for
2006–2025.
For projecting future rates the Nordpred software uses the
age-period-cohort (APC) models, deriving the relevant parameters
from the past observations and using them to estimate future rates.
Here, the age, period and cohort function as pseudo indicators for
factors that have influenced past trends, such as exposure to risk
factors, treatment or screening affecting certain age groups,
periods or cohorts. Within the basic APC model, the Nordpred
software allows the choice of several options for modelling and
projecting incidence and mortality rates. For this study, we used
the model found by the Nordic research group to give the most
accurate predictions of future numbers of 20 different cancer types
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link function in poisson regression, the power of 5 was used. The
reasoning behind this is that the power function levels of a potential
exponential increase (so as to keep projections closer to the
observed rates). The model can be written as
Rap ¼ð Aa þ D   p þ Pp þ CcÞ
5
where Rap is the mortality rate for age group a and period p, Aa is
the age effect of age group a, D is the common linear drift of period
and cohort, Pp is the non-linear period effect and Cc is the non-
linear cohort effect, where c¼p a. Note that the 5-year periods are
numbered consecutively so that p increases by 1 every 5 years;
similarly, a counts 5-year age groups.
Those age groups for which less than 50 deaths were observed
during any 5-year period were not included in any period in the
modelling.
The age component was projected directly when estimated. For
age groups not included in the model, the mean observed mortality
for 1996–2005 was used for projections.
The linear drift D was projected into the future, but with
two modifications. The so-called cut trend system was used, in the
sense that instead of adding D for each future period, we added D,
3/4 D, 1/2 D and 1/4 D in the four future 5-year periods.
The reasoning behind this was that whatever might have caused
the increase or decrease in the past is not likely to continue
unchanged indefinitely; rather some attenuation of such
influences seems more plausible. In addition, Nordpred checks
for significant curvature in the trends of the observed rates, and if
this was present, the change in the last 10 years (recent slope),
instead of the average change in the whole period (average slope),
was used as the drift component in the future projections.
The rationale is that the factors responsible for the most recent
trends (when there has been a change) are more likely to be an
influence on future rates, rather than those operative in the more
distant past.
The non-linear cohort component was projected for estimated
cohorts. For young cohorts not estimated, the last estimated cohort
component was used.
The projections assume that the last non-linear period
component applies to all future periods.
To estimate future rates for all cancers combined, the ‘other
cancers’ category (i.e., other than the 21 sites studied) was created,
and projected rates were calculated, as for the other sites. The total
Table 1 Observed and projected numbers of deaths by cancer site and projected change in mortality for (a) men and (b) women in the United Kingdom
ICD10 Cancer type
Deaths
2003
Deaths
2023
Overall
change (%)
Change
in risk (%)
Additional
change
(a)
C00-06, C09-10, C12-14 Oral 1100 1594 45 3 42
C15 Oesophagus 4657 7114 53 2 51
C16 Stomach 3748 3275  13  43 31
C18 Colon 5317 5838 10  32 42
C19-21 Rectum 3276 4387 34  13 47
C22 Liver 1520 2537 67 14 53
C25 Pancreas 3367 4763 41  64 8
C32 Larynx 667 743 11  25 37
C33-34 Lung 19866 20542 3  31 34
C43 Malignant melanoma 927 1449 56 8 48
C64-66 Kidney 2114 2864 35  11 46
C61 Prostate 10039 15469 54  12 67
C67 Bladder 3203 3776 18  32 49
C71 Brain and other CNS 1984 2327 17  11 29
C82-85 Non-Hodgkin’s lymphoma 2410 2886 20  23 42
C88, C90 Multiple myeloma 1314 1982 51  45 5
C91-95 Leukaemia 2375 3674 55  35 8
C00-97 (excluding C44) All cancer except
non-melanoma skin cancer
79801 103626 30  17 47
(b)
C00-06, C09-10, C12-14 Oral 571 746 31 0 31
C15 Oesophagus 2593 2875 11  17 28
C16 Stomach 2328 2008  14  36 22
C18 Colon 5190 4470  14  36 22
C19-21 Rectum 2363 2895 22  83 1
C22 Liver 1076 1426 33 0 32
C25 Pancreas 3626 4378 21  93 0
C32 Larynx 171 151  12  32 20
C33-34 Lung 13521 15211 12  14 26
C43 Malignant melanoma 803 829 3  22 25
C50 Breast 12642 11834  6  28 21
C53 Cervix 1110 609  45  57 11
C54 Corpus uteri 1093 1716 57 18 39
C56-57 Ovary 4563 4694 3  21 24
C64-66 Kidney 1325 1587 20  92 9
C67 Bladder 1669 1752 5  23 28
C71 Brain and other CNS 1425 1439 1  21 22
C82-85 Non-Hodgkin’s lymphoma 2176 2205 1  24 25
C88,C90 Multiple myeloma 1231 1460 19  11 30
C91-95 Leukaemia 1905 2277 20  11 30
C00-97 (excluding C44) All cancer except non-melanoma skin cancer 73909 82415 12  16 27
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the individual sites (including ‘other cancers’) divided by the
population numbers.
The projected numbers of deaths were calculated using the
projected mortality rates and the population projections from
the Government Actuary’s department (2007). In the tables, the
numbers for 2023 are presented using the average population
projections and the mortality rates for 2021–2025. The numbers
for 2003 are presented using the average observed numbers for the
corresponding 5-year period, 2001–2005.
Mortality rates are presented as age-standardised rates, accord-
ing to the European standard population (Doll and Smith, 1982).
In 1984, the rules used to interpret secondary causes of death
changed. In 1993, the rules from before 1984 were used again, and,
in addition to this, the extent to which non-specific causes of death
automatically generated medical enquiries changed. Estimates of
the effects of these changes on disease-specific mortality rates have
been published (Office of Population Censuses and Surveys, 1996).
Age-specific mortality rates for the period 1971–1992 were
adjusted to the coding practices from 1993 onwards using the
factors in Table A.3 and B in the publication mentioned above
(Office of Population Censuses and Surveys, 1996).
RESULTS
Figure 1 shows the trends and projections of the age-standardised
mortality rates for cancer (all sites) for men and women. Figure 2
shows the age-specific trends and projections for cancer mortality
rates (all sites) for men (2A) and women (2B). Figure 3 shows
trends and projections for 21 different cancers, by sex.
Table 1 shows, for men and women, the observed numbers of
deaths by cancer site in 2003, and the numbers projected in 2023.
The percentage change in the numbers of deaths is expressed as a
percentage of the 2003 figures (% change overall), and this is
divided into the component that results from the changes in
mortality rates (risk) and the remainder, which is a consequence of
demographic trends in the size and age composition of the
population.
Mortality rates from cancer as a whole have been falling in the
United Kingdom since 1990, and this decline is projected to
continue into the future (Figure 1). For men as well as women, the
decrease started earlier in the younger age groups indicating a
cohort effect (Figure 2). The actual projected decrease in the age-
standardised mortality rates between 2003 and 2023 is 17% in men
and 16% in women. The projected increase in population size (59.6
million in 2003 and 68.0 million in 2023) and population ageing
(11.5% aged 70 years or above in 2003, 14.7% in 2023) would result
in an increase in the number of cancer deaths (by 57% in men and
31% in women), even if mortality rates remain unchanged. The
combined effect of the increase because of demography and
decrease because of declining rates is projected 30% increase in
cancer deaths in men in the 20-year period and a 12% increase for
women (Table 1).
Inspection of the trends and projections of mortality for the
different cancers suggests declining future rates in both sexes for
most cancers. In men, there are small projected increases in
mortality rates from cancers of the oral cavity, oesophagus and
melanoma, with a larger projected increase (14% over 20 years) in
mortality from cancer of the liver. In women, only the age-adjusted
mortality rate from cancer of the corpus uteri is projected to
increase (by 18% over 20 years).
Despite these declines in mortality rates, the actual numbers of
deaths will increase for most cancers, the exceptions being cancer
of the stomach in men, and cancers of stomach, colon, larynx,
cervix and breast in women.
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Figure 1 Trends and projections of the age-standardised (Europe)
mortality rates for cancer (all sites except non-melanoma skin cancer) for
men and women in the United Kingdom.
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Figure 2 Age-specific trends and projections for cancer mortality rates
(all sites except non-melanoma skin cancer) for men (A) and women (B)
in the United Kingdom.
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yDISCUSSION
Our projections of future mortality in the United Kingdom
envisage declining rates of mortality for most cancer sites (and
overall).
Future projections depend on multiple assumptions, but the basic
premise is that past trends, affecting as they do the risk of death
from cancer in specific generations and/or time periods, will be
carried forward into the future. The Nordpred package allows for
two additional assumptions — that recent trends are more relevant
to the future evolution of risk than those in the distant past and that
the impact of the factors underlying them (whatever they may be)
will progressively diminish (the basis of the arbitrary reduction in
the ‘drift’ component of the model in each 5-year period).
Projections do not take into account the impact of possible
future changes in the incidence of cancer, or of dying from cancer,
other than in a general way. They are, therefore, a useful basis for
examining the possible scenarios resulting from the changes in
policy with respect to prevention, screening or treatment (Black
and Stockton, 2001; Parkin et al, 2008).
The projected numbers of deaths are dependant on reasonable
population projections. In this study, we used the 2006-based
population projections prepared by the Government Actuary’s
Department.
Møller et al (2007) carried out a similar analysis, using the same
methodology, with respect to cancer incidence in England. In that
study, 2004-based population projections were used. The projected
population size in 2023 is 4% larger using the 2006-based
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most of the differences concern the youngest and very oldest age
groups. The variation at ages 50–79 (where 60% of cancer deaths
occur) is small (o1%). Although incidence rates in men were
projected to decline by 7% between 2001 and 2020 (driven largely
by the declining rates of lung cancer), female rates were projected
to increase by the same amount, with significant increases in the
risk of breast cancer in particular. The differences between the
projections of mortality and those of incidence (other than the
somewhat different populations studied – the United Kingdom and
England, respectively) are in part explained by the improvement in
prognosis for some cancers in recent years, partly as a result of
screening and partly because of better treatment. Thus, in England,
survival rates have increased between 1986 and 1999 for several
major cancers – at 1% annually for cancers of the breast and colon-
rectum, around 0.6–0.8% annually for cancers of the ovary,
kidney, melanoma, leukaemia and lymphoma and by 2.3% for
cancer of the prostate (Cancer Research UK, 2007). This is
particularly obvious for cancer of the breast – the second most
common cancer in United Kingdom – for which incidence rates
have, until very recently, been increasing, whereas mortality has
declined since 1988 (Cancer Research UK, 2008). Similarly, the
incidence of prostate cancer in men in the United Kingdom
increased by 4.1% annually since 1994, whereas mortality has
declined by 1.1% a year (Cancer Research UK, 2008).
In this study, we have projected cancer mortality rates 20 years
into the future. Projections are more likely to be close to reality in
the near future. However, programmes of early detection and, even
more so, prevention will not influence mortality rates for many
years after their introduction. The projections in this paper form
the basis for research into the effect of various scenarios for
interventions such as these, as well as improvements in treatment
and the delivery of cancer services, so that a period of at least 20
years is necessary to fully evaluate their potential effects.
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